New Drug Approvals

Home » 2013 (Page 49)

Yearly Archives: 2013

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Blog Stats

  • 4,817,828 hits

Flag and hits

Flag Counter

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
Follow New Drug Approvals on WordPress.com

Archives

Categories

Recent Posts

Flag Counter

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

Verified Services

View Full Profile →

Archives

Categories

Flag Counter

Flow synthesis for Novartis anticancer drug, Gleevec, Imatinib


flow synthesis

The flow-based route required minimal manual intervention and was achieved despite poor solubility of many reaction components

21 January 2013Michael Parkin

UK chemists have used a combination of flow chemistry methods with solid-supported scavengers and reagents to synthesise the active pharmaceutical ingredient, imatinib, of the anticancer drug Gleevec. The method avoids the need for any manual handling of intermediates and allows the drug to be synthesised in high purity in less than a day.

Gleevec, developed by Novartis, is a tyrosine kinase inhibitor used for the treatment of chronic myeloid leukaemia and gastrointestinal stromal tumours.

READ ALL AT

http://www.rsc.org/chemistryworld/2013/01/flow-synthesis-anticancer-drug

IMATINIB

CREDIT

http://www.veomed.com/va041542042010

‘Wrapping’ Gleevec Fights Drug-Resistant Cancer, Study Shows

 http://www.sciencedaily.com/releases/2007/05/070501115127.htm

The anti-cancer drug Gleevec® is far more effective against a drug-resistant strain of cancer when the drug wraps the target with a molecular bandage that seals out water from a critical area. This image shows the bandage (black box) on the modified version of the drug, WBZ-7. (Credit: Image courtesy of Rice University)

A new study in Cancer Research finds that the anti-cancer drug Gleevec® is far more effective against a drug-resistant strain of cancer when the drug wraps the target with a molecular bandage that seals out water from a critical area.

FDA Grants Priority Review To New Drug Application For MNK-795


FDA Grants Priority Review To New Drug Application For MNK-795 Submitted By Depomed Licensee Mallinckrodt

Controlled Substance Analgesic Combination Product Uses Depomed’s Proprietary Acuform® Technology

NEWARK, Calif., July 29, 2013 /PRNewswire/ — Depomed, Inc. (NASDAQ:DEPO) announced today that the U. S. Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Mallinckrodt (NYSE: MNK) for MNK-795.  MNK-795 is a controlled-release oral formulation of oxycodone and acetaminophen that has been studied for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate.  MNK-795 is formulated with Depomed’s Acuform® drug delivery technology.

 

http://www.pharmalive.com/fda-grants-priority-review-to-new-drug-application-for-mnk-795

Considerations in the clinical development of biotech medicines


Biomarkers in oncology drug development


http://www.topra.org/sites/default/files/regrapart/1/2452/focus1.pdf



Regulatory update: albiglutide US PDUFA date extended by three months


albiglutide,

Friday 2 August 2013, London UK

GlaxoSmithKline plc (LSE:GSK) today announced that the US Prescription Drug User Fee Act (PDUFA) goal date for albiglutide, an investigational once-weekly treatment for adult patients with type 2 diabetes, has been extended by three months to 15 April 2014 to provide time for a full review of information submitted by GSK in response to the Food and Drug Administration’s requests.

http://www.pharmalive.com/fda-delays-approval-decision-for-gsk-s-albiglutide

Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist) drug under investigation by GlaxoSmithKline for treatment oftype 2 diabetes. It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin.

Albiglutide has a half-life of four to seven days, which is considerably longer than the other two GLP-1 analogs approved for market use, exenatide (Byetta) and liraglutide (Victoza). GLP-1 drugs are currently only available for subcutaneous administration on a daily basis, so a GLP-1 drug with a longer half-life is desirable. Such a drug would only need to be injected biweekly or weekly instead of daily, reducing the discomfort and inconvenience of GLP-1 administration considerably.

It has not yet been determined whether albiglutide is as effective an antidiabetic agent as GLP-1 drugs currently on the market, and final data remain to be published regarding the incidence of adverse effects related to the drug. To evaluate the efficacy and safety of the drug, albiglutide is undergoing eight Phase III clinical trials. Four of these trials should report useful data by end 2010

…………………………….

………..

 

Patent Battle Over Generic Drug Trade in India


Rahul Dev's avatarBiotech Patent Expert Lawyer India| IPR International Medical Law Firm in India Delhi|Patent Attorneyl Research Services| Patent Portfolio Analytics | Freedom to Operate FTO| Tech Monitoring Service| Patent Services Offshoring | Patent Research Outsourcing | Intellectual Property Services | India Patent Filling

Patent Battle Over Generic Drug Trade in India

India’s Patent rules for drug trade is grabbing global eyeballs ever since we acceded to WTO agreement in 2005. Recent court rulings have again raised a major debate on Indian rules join in our discussions about technology and business in today’s world failing to protect IPR of original inventors.

Source: Life Science India
You can also check out our premium service offerings for Mobile Applications, Social Media & Cyber Laws and Pharmaceuticals, Biotechnology, Food & Healthcare We regularly update our Facebook page and share similar stories on TwitterDo have a look at our fresh tweets, news items and articles, and join in our discussions about technology and business in today’s world.

To know more about us, get connected with us on LinkedIn or mail us at info [at] techcorplegal [dot] com.
Patent Technology Practice Areas:…

View original post 139 more words

Patent Searching in India| Patent Searcher in India | India Patent – Patent Guide for Inventors


Biotech Patent Expert Attorney in India's avatarBiotech Patent Expert Lawyer India| IPR International Medical Law Firm in India Delhi|Patent Attorneyl Research Services| Patent Portfolio Analytics | Freedom to Operate FTO| Tech Monitoring Service| Patent Services Offshoring | Patent Research Outsourcing | Intellectual Property Services | India Patent Filling

Medical Devices: Technology, Emerging Sectors, Patent Trends and Roadblocks

Bio Corp Legal denotes premium service offerings offered by Tech Corp Legal LLP, an international law firm in India focusing on technology laws and business intelligence services.

We provide IP business services in the following domains:

  • Pharma
  • Biotech
  • Medical Diagnostics
  • Cell Based Research
  • Cell & Gene Therapy
  • Food Tech
  • Peptides
  • Biological Manufacturing Chemical based technologies
  • Healthcare
  • Drug Approval
  • Life Sciences & related industries.

Online Patent Searching Tools

 

USPTO
Full Text Search
US Patent Office – Full Text Boolean Search

US Patent Office – Full Text Advanced Search

US Patent Office – Full Text Patent Number Search

US Patent Office – Patent Images

US Patent Office – Classification Index


Help
USPTO Applications Full Text Search

US Patent Office – Full Text Boolean Search

US Patent Office – Full Text Advanced Search

US Patent Office – Full Text Patent Number…

View original post 517 more words

Japanese Patent Applications can be translated to English by EPO’s Automatic Machine Translation


Rahul Dev's avatarBiotech Patent Expert Lawyer India| IPR International Medical Law Firm in India Delhi|Patent Attorneyl Research Services| Patent Portfolio Analytics | Freedom to Operate FTO| Tech Monitoring Service| Patent Services Offshoring | Patent Research Outsourcing | Intellectual Property Services | India Patent Filling

Japanese Patent Applications can be translated to English by EPO’s Automatic Machine Translation

japanese_patent

Today EPO and the Japan Patent Office (JPO) announced the launch of the Japanese-English component of the EPO’s automatic translation service Patent Translate. This is a very good news for patent applicants and inventors across the globe as they can now easily translate the patent published in Japanese language. Numerous Japanese patent specifications available via the EPO’s global patent database Espacenet (www.epo.org/espacenet) can now be translated into English at zero cost to the applicant.

Recently, EPO and Google have been working together for sometime now to provide translation service optimised for patent specifications. Currently, patent translate covers translations between English and 15 other languages, namely Chinese, Danish, Dutch, Finnish, French, German, Greek, Hungarian, Italian, Japanese, Norwegian, Polish, Portuguese, Spanish and Swedish. In the time to come more languages will be added to the database.

Patent Translate

Patent Translate…

View original post 744 more words

World Drug Tracker: MICROENCAPSULATION: ADVANCEMENTS IN TECHNOLOGY AND ITS PATENTS


World Drug Tracker: MICROENCAPSULATION: ADVANCEMENTS IN TECHNOLOGY AND ITS PATENTS.

DENDRIMER: A NOVEL SYSTEM IN PHARMACEUTICALS | EUREKAMOMENTS IN ORGANIC CHEMISTRY


DENDRIMER: A NOVEL SYSTEM IN PHARMACEUTICALS | EUREKAMOMENTS IN ORGANIC CHEMISTRY.